SMN2 and proximal spinal muscular atrophy: Proof of concept has been demonstrated by a significant increase in full-length SMN2 pre-mRNA and higher levels of SMN protein in motor neurons, observed after antisense-mediated targeting of ISS-N1 in transgenic mouse models of SMA [61,63,64] and in human clinical trials [65].